The present work demonstrates that co-targeting G9a/DNMT1 in NSCLC represents a novel antitumor strategy in NSCLC, with SCARA5 and AOX1 as mediators of the cytotoxic activity and SCARA5 DNA methylation as potential companion biomarker. Here, EHMT2 is linked to non-small cell lung carcinoma.